Return Of In-Person Psychiatry Visits Could Lift Neurocrine’s Ingrezza
Only One In Four TD Patients Currently Offered Treatment
Executive Summary
Ingrezza became a $1bn therapy in 2022 despite the pandemic, but Neurocrine expect many more patients are diagnosed and treated if the pandemic eases as hoped.